Stockreport

Trial Results of Mesoblast Cell Therapy in End-Stage Heart Failure Selected as Late-Breaking Presentation at 2018 American Heart Association Scientific Sessions

Mesoblast Limited - American Depositary Shares  (MESO) 
US:NASDAQ Investor Relations: investorsmedia.mesoblast.com
PDF NEW YORK and MELBOURNE, Australia, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the 159-patient randomized placebo-c [Read more]